• Acadia Pharmaceuticals Inc., of San Diego, said the FDA cleared schizophrenia drug AM-831 to begin a Phase I trial. AM-831 is a small molecule that combines muscarinic m1 partial agonism with dopamine D2 and serotonin 5-HT2A antagonism. The drug was discovered by Acadia and developed in collaboration with Tokyo-based Meiji Seika Kaisha Ltd., under the companies' 2009 antipsychotic deal for Asian territories.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter